A significant challenge in the field of nervous system pathologies lies in the absence of effective treatments. MAAsiRNA develops a pioneering targeted therapy utilizing small interfering RNA (siRNA).
After over a decade of intensive interdisciplinary research, we have successfully developed a siRNA-based treatment for Charcot-Marie-Tooth disease type 1A (CMT1A), the most prevalent form of hereditary peripheral neuropathy. CMT1A affects 1 in 5000 people, comprising a total of 1.5 million individuals worldwide. Our current objective is to advance towards a patient-ready therapy. Our innovative therapeutic approach has the potential to be adapted for other disorders within the nervous system.
Company Details
- Employees
- 6
- Founded
- 2023
- Address
- 1 Rue Du Belvedere, Palaiseau,91120,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://maasirna.com
- Keywords
- Dijon.
- HQ
- Palaiseau
Maasirna Questions
Maasirna's website is http://maasirna.com
Maasirna's LinkedIn profile is https://fr.linkedin.com/company/maasirna
Maasirna has
6 employees.
View email and phone details for 6
employees at Maasirna.
Maasirna's industry is
Biotechnology Research
Maasirna's top competitors are
Crm - Centre De Recherche En Myologie,
4bbiosearch,
Therapixel,
Robocath,
Urgo Advanced Textile,
Cair Lgl,
Sensome,
Floralis,
Inrae,
Cedafis Consulting.
Maasirna's categories are Biotechnology Research
Maasirna's founding year is 2023
